Stocktoria
Akebia Therapeutics, Inc. AKBA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-03-20
Akebia Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $236.2M | $160.2M | $194.6M | $292.5M | $213.6M |
| R&D expense | $62.4M | $37.7M | $63.1M | $130.0M | $147.9M |
| SG&A expense | $107.5M | $106.5M | $100.2M | $138.6M | $174.2M |
| Operating income | $23.5M | -$50.5M | -$46.3M | -$80.8M | -$265.3M |
| Income tax | $1.6M | $0 | $0 | $0 | $0 |
| Net income | -$5.3M | -$69.4M | -$51.9M | -$94.2M | -$282.0M |
| EPS (diluted) | $-0.02 | $-0.33 | $-0.28 | $-0.52 | $-1.70 |
| Operating cash flow | $68.0M | -$40.7M | -$23.4M | -$73.2M | -$253.0M |
| Free cash flow | $67.7M | -$40.7M | -$23.4M | -$73.3M | -$253.0M |
| Cash & equivalents | $184.8M | $51.9M | $42.9M | $90.5M | $149.8M |
| Inventory | $15.6M | $16.2M | $15.7M | $21.6M | $38.2M |
| Total assets | $376.6M | $220.7M | $241.7M | $356.1M | $525.5M |
| Total liabilities | $344.0M | $269.9M | $272.3M | $350.8M | $449.1M |
| Shareholders' equity | $32.6M | -$49.2M | -$30.6M | $5.2M | $74.0M |
Source: SEC EDGAR filings · CIK 0001517022 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.